Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 10/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29839302 | 0.87 | RIPK1 (0.47) | EPHX2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL22729426 | 0.87 | RIPK1 (0.47) | EPHX2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL22754898 | 0.86 | NAAA (0.41) | NAAAEPHX2CYP2C9 | |
| SCHEMBL22729583 | 0.84 | RBP4 (0.41) | EPHX2CYP2C9KDM4EALDH1A1HSD17B10 | |
| SCHEMBL22729640 | 0.83 | CYP46A1 (0.41) | EPHX2CYP2C9KDM4EALDH1A1HSD17B10 | |
| SCHEMBL23116383 | 0.81 | GAA (0.38) | KDM4EALDH1A1HSD17B10HPGDTP53 | |
| SCHEMBL22729839 | 0.81 | ALDH1A1 (0.43) | KDM4EALDH1A1HSD17B10HPGDTP53 | |
| SCHEMBL22729528 | 0.80 | EPHX2 (0.42) | EPHX2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL22729684 | 0.79 | SPR (0.44) | EPHX2KDM4EALDH1A1HSD17B10HPGD | |
| SCHEMBL23116376 | 0.79 | KDM4E (0.46) | EPHX2KDM4EALDH1A1HSD17B10HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459325-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-10-04 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | US | disclosed |
| EP-3747885-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-12-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087186-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | NAAA 145/4885EPHX2 2093/4885CYP2C9 4675/4885 |
| US-11459325-B2 | Heterocyclic compound | GBA1, GBA2, GALC | NAAA 153/4885EPHX2 2011/4885CYP2C9 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.